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Genome-wide association study results for
educational attainment aid in identifying genetic
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Higher educational attainment (EA) is negatively associated with schizophrenia (SZ). How-
ever, recent studies found a positive genetic correlation between EA and SZ. We investigate
possible causes of this counterintuitive ﬁnding using genome-wide association study results
for EA and SZ (N= 443,581) and a replication cohort (1169 controls; 1067 cases) with deeply
phenotyped SZ patients. We ﬁnd strong genetic dependence between EA and SZ that cannot
be explained by chance, linkage disequilibrium, or assortative mating. Instead, several genes
seem to have pleiotropic effects on EA and SZ, but without a clear pattern of sign con-
cordance. Using EA as a proxy phenotype, we isolate FOXO6 and SLITRK1 as novel candidate
genes for SZ. Our results reveal that current SZ diagnoses aggregate over at least two disease
subtypes: one part resembles high intelligence and bipolar disorder (BIP), while the other part
is a cognitive disorder that is independent of BIP.
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Schizophrenia (SZ) is the collective term used for a severe,highly heterogeneous and costly psychiatric disorder that iscaused by environmental and genetic factors1–4. A genome-
wide association study (GWAS) by the Psychiatric Genomics
Consortium (PGC) identiﬁed 108 genomic loci that are associated
with SZ5. These 108 loci jointly account for ≈3.4% of the variation
on the liability scale for SZ5, while all single-nucleotide poly-
morphisms (SNPs) that are currently measured by SNP arrays
capture ≈64% (s.e.= 8%) of the variation in liability for the dis-
ease6. This implies that many genetic variants with small effect
sizes contribute to the heritability of SZ, but most of them are
unidentiﬁed as of yet. A polygenic score (PGS) based on all SNPs
currently accounts for 4–15% of the variation on the liability scale
for SZ5.
Yet, this PGS does not predict any differences in symptoms or
severity of the disease among SZ patients4. Partly, this could be
because the clinical disease classiﬁcation of SZ spans several
different behavioural and cognitive traits that may not have
identical genetic architectures. Therefore, identifying additional
genetic variants and understanding through which pathways they
are linked with the clinical diagnosis of SZ is an important step in
understanding the aetiologies of the ‘schizophrenias’7. However,
GWAS analyses of speciﬁc SZ symptoms would require very large
sample sizes to be statistically well-powered, and the currently
available data sets on deeply phenotyped SZ patients are not yet
large enough for this purpose.
Here, we use an alternative approach to make progress with
data that is readily available—by combining GWAS for SZ and
educational attainment (EA). Previous studies suggest a complex
relationship between EA and SZ8 that may be used to gain
additional insights into the genetic architecture of SZ and its
symptoms. In particular, phenotypic data seem to suggest a
negative correlation between EA and SZ9. For example, SZ
patients with lower EA typically show an earlier age of disease
onset, higher levels of psychotic symptomatology and worsened
global cognitive function9. In fact, EA has been suggested to be a
measure of premorbid function and a predictor of outcomes in
SZ. Moreover, it has been forcefully argued that retarded intel-
lectual development, global cognitive impairment during child-
hood and bad school performance should be seen as core features
of SZ that precede the development of psychotic symptoms and
differentiate SZ from bipolar disorder (BIP)10–14. Furthermore,
credible genetic links between SZ and impaired cognitive per-
formance have been found15.
In contrast to these ﬁndings, recent studies using large-scale
GWAS results identiﬁed a small, but positive genetic correlation
between EA and SZ (ρEA,SZ= 0.08)8, and higher PGS values for
SZ have been reported to be associated with creativity and
greater EA16. Other statistically well-powered studies found
that a high intelligence quotient (IQ) has protective effects
against SZ17 and reported a negative genetic correlation
between IQ and SZ (ρIQ,SZ= –0.2)18, suggesting the possibility
that genetic effects that contribute to EA but not via IQ
are responsible for the observed positive genetic correlation
between SZ and EA.
Indeed, previous research by the Social Science Genetic Asso-
ciation Consortium (SSGAC)8 already demonstrated that the
effect of the EA-PGS on years of schooling is mediated by several
individual characteristics that have imperfect or no genetic cor-
relation with each other, including higher IQ, higher openness
and higher conscientiousness. These different factors that con-
tribute to EA seem to be related to SZ and its symptoms in
complex ways19–21. For example, differences in openness have
been reported to differentiate between patients diagnosed with SZ
spectrum personality disorders (higher openness) from patients
diagnosed with SZ (lower openness), while conscientiousness
tends to be reduced among patients of both disorders compared
to healthy controls19.
The contributing factors to EA that have previously been iden-
tiﬁed by the SSGAC (i.e. IQ, openness and conscientiousness)8 are
phenotypically and genetically related, but by no means
identical22,23. Speciﬁcally, the Cognitive Genomics Consortium
(COGENT) reported a moderate genetic correlation between IQ
and openness (rg= 0.48, P= 3.25 × 10–4), but only a small genetic
correlation of IQ and conscientiousness of 0.10 that was indis-
tinguishable from zero (rg= 0.10, P= 0.46)24. Therefore, it is
appropriate to think of EA as a genetically heterogeneous trait
that can be decomposed into subphenotypes that have imperfect
genetic correlations with each other. If the various symptoms of
SZ also have non-identical genetic architectures, this could result
in a pattern where both EA and SZ share many genetic loci, but
without a clear pattern of sign concordance and with seemingly
contradictory phenotypic and genetic correlation results.
To explore this hypothesis and to discern it from alternative
explanations, we perform a series of statistical genetic analyses
using large-scale GWAS results for SZ and EA from non-
overlapping samples. We start by characterizing the genetic
relationship between both traits by using EA as a ‘proxy pheno-
type’25 for SZ. We annotate possible biological pathways, tissues
and cell types implied by genetic variants that are associated with
both traits and explore to what extent these variants are also
enriched for association with other traits. We test if the genetic
relationship between EA and SZ can be explained by chance,
linkage disequilibrium (LD) or assortative mating. Furthermore,
we investigate the hypothesis that the part of SZ that is different
from BIP is a neurodevelopmental disorder, whereas the part of
SZ that overlaps with BIP is not. Finally, we develop a formal
statistical test for genetic heterogeneity of SZ using a polygenic
prediction framework that leverages both the SZ and the EA
GWAS results. Together, our analysis suggest that current SZ
diagnoses aggregate over at least two disease subtypes: one part
resembles BIP and high IQ, while the other part is a cognitive
disorder that is independent of BIP.
Results
Genetic dependence and genetic correlation. As a formal pre-
lude to our study, it is conceptually important to differentiate
between genetic dependence and genetic correlation. In our
analyses, genetic dependence means that the genetic variants
associated with EA are more likely to also be associated with SZ
than expected by chance. In contrast, genetic correlation is
deﬁned by the correlation of the (true) effect sizes of genetic
variants on the two traits. Thus, genetic correlation implies a
linear genetic relationship between two traits whereas genetic
dependence does not. Thus, two traits can be genetically depen-
dent even if they are not genetically correlated and vice versa. One
possible cause of a non-linear genetic dependence is that at least
one of the traits is genetically heterogeneous in the sense that it
aggregates across subphenotypes (or symptoms) with non-
identical genetic architectures. Supplementary Note 1 presents a
formal discussion and simulations that illustrate the data patterns
that can emerge.
Proxy-phenotype analyses. We used the proxy-phenotype
method (PPM)25 to illustrate the genetic dependence between
EA and SZ. PPM is a two-stage approach. In the ﬁrst stage, a
GWAS on the proxy-phenotype (EA) is conducted. The most
strongly associated loci are then advanced to the second stage,
which tests the association of these loci with the phenotype of
interest (SZ) in an independent sample. If the two traits are
genetically dependent, this two-stage approach can increase the
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statistical power for detecting associations for the target trait
because it limits the multiple testing burden for the phenotype of
interest compared to a GWAS8,25,26.
Our PPM analyses followed a preregistered analysis plan
(https://osf.io/dnhfk/) using GWAS results on EA (n= 363,502)8
and SZ (34,409 cases and 45,670 controls)5 that were obtained
from non-overlapping samples of Europeans. For replication and
follow-up analyses, we used the Göttingen Research Association
for Schizophrenia (GRAS) data collection27, which has a uniquely
rich and accurate set of SZ measures. The GRAS sample was not
part of either GWAS.
Analyses were performed using 8,240,280 autosomal SNPs that
passed quality controls in both GWAS and additional ﬁlters. We
selected approximately independent lead SNPs from the EA
GWAS that passed the predeﬁned signiﬁcance threshold of PEA <
10–5 and looked up their SZ results. To test if EA-associated SNPs
are more strongly associated with SZ than expected by chance
(referred to as ‘raw enrichment’ below), we conducted a
Mann–Whitney test that compares the PSZ values of the EA-
associated lead SNPs with the PSZ values of a set of randomly
drawn, approximately LD-independent SNPs with similar minor
allele frequencies (MAFs). Fig. 1 presents an overview of the
proxy-phenotype analyses.
The ﬁrst-stage GWAS on EA identiﬁed 506 loci that passed our
predeﬁned threshold of PEA < 10–5 (Supplementary Note 2); 108
of them were signiﬁcant at the genome-wide level (PEA < 5 × 10–8,
see Supplementary Data 2). Of the 506 EA lead-SNPs, 132 are
associated with SZ at nominal signiﬁcance (PSZ < 0.05), and 21 of
these survive Bonferroni correction (PSZ < 0:05506 = 9.88 × 10
−5)
(Table 1). LD score regression results suggest that the vast
majority of the association signal in both the EA8 and the SZ5
GWAS are truly genetic signals, rather than spurious signals
originating from uncontrolled population stratiﬁcation. Fig. 2a
shows a Manhattan plot for the GWAS on EA highlighting SNPs
that were also signiﬁcantly associated with SZ (black crosses for
PSZ < 0.05, magenta crosses for PSZ= 9.88 × 10–5).
A Q–Q plot of the 506 EA lead SNPs for SZ is shown in Fig. 2b.
Although the observed sign concordance of 52% is not
signiﬁcantly different from a random pattern (P= 0.40), we ﬁnd
3.23 times more SNPs in this set of 506 SNPs that are nominally
signiﬁcant for SZ than expected given the distribution of the
P values in the SZ GWAS results (raw enrichment P= 6.87 ×
10−10). The observed enrichment of the 21 EA lead SNPs that
pass Bonferroni correction for SZ (PSZ < 0:05506 = 9.88 × 10
−5) is
even more pronounced (27 times stronger, P= 5.44 × 10−14).
The effect sizes of these 21 SNPs on SZ are small, ranging from
odds ratio (OR)= 1.02 (rs4500960) to OR= 1.11 (rs4378243)
after correction for the statistical winner’s curse25 (Table 1). We
calculated the probability that these 21 SNPs are truly associated
with SZ using a heuristic Bayesian method that takes the winner’s
curse corrected effect sizes, statistical power and prior beliefs into
account25. Applying a reasonable prior belief of 5%, we ﬁnd that
all 21 SNPs are likely or almost certain to be true positives.
Novel SZ loci. Of the 21 variants we identiﬁed, 12 are in LD with
loci previously reported by the PGC5 and two are in the major
histocompatibility complex region on chromosome (chr) 6 and
were therefore not separately reported in that study. Three of the
variants we isolated (rs7610856, rs143283559 and rs28360516)
were independently found in a meta-analysis of the PGC results5
with another large-scale sample which identiﬁed 50 novel SZ
SNPs28. Two of the 21 variants (rs756912, rs7593947) are in LD
with loci recently reported in a study that also compared GWAS
ﬁndings from EA and SZ using smaller samples and a less con-
servative statistical approach29. The remaining two SNPs we
identiﬁed here (rs7336518 on chr13 and rs7522116 on chr1) add
to the list of empirically plausible candidate loci for SZ.
Using a proportions test, we compared the ratio of novel SNPs
from ref.28 included in our list of 132 loci that are jointly
associated with EA and SZ (PEA < 10−5 and PSZ < 0.05, yielding 6
loci) with the ratio observed in all remaining approximately
independent loci with PSZ < 0.05 in our SZ GWAS results. We
found that the proportion of novel SZ SNPs is higher among the
132 loci that are informed by the EA GWAS results (Fisher’s
exact test P= 2.4 × 10−9, two-sided). Thus, using EA as a proxy-
phenotype for SZ helped to predict the novel genome-wide
signiﬁcant ﬁndings reported in ref.28, illustrating the power of the
proxy-phenotype approach.
Detection of shared causal loci. The next step in our study was a
series of analyses that aimed to identify reasons for the observed
genetic dependence between EA and SZ and to put the ﬁndings of
the PPM analysis into context. First, we probed if there is evi-
dence that the loci identiﬁed by the PPM may tag shared causal
loci for both EA and SZ (i.e. pleiotropy), rather than being in LD
with different causal loci for both traits.
For each of the 21 SNPs isolated by our PPM analysis, we
looked at their neighbouring SNPs within a ±500 kb window and
estimated their posterior probability of being causal for EA or SZ
using PAINTOR30. We then selected two sets of SNPs, each of
which contains the smallest number of SNPs that yields a
cumulative posterior probability of 90% or 50% of containing
the causal locus for EA and SZ. We refer to these as broad sets
(90%) and narrow sets (50%), respectively. Supplementary
Note 3 and Supplementary Data 4 also contain results for the
80 and 65% credibility sets. For each of these sets, we calculated
the posterior probability that it contains the causal locus for the
other trait.
For the broad credibility set analyses (90%), we found 11 loci
with a medium or high credibility to have direct causal effects on
both EA and SZ (including one of the novel SNPs, rs7336518). Six
of these loci have concordant effects on the two traits (i.e. ++ or
−−) while ﬁve have discordant effects (i.e. +− or −+, Table 1).
The analyses of the 50% credible sets are based on a smaller number
of SNPs. This also results in lower probabilities that the SZ set
contains the causal SNP for EA and vice versa. Nevertheless, our
analysis with 50% credible sets show that four speciﬁc loci
(rs7610856, rs320700, rs79210963 and rs7336518) had credibility
of more than 15% for the other trait, providing support for the high
(rs320700 and rs79210963) and medium (rs7610856 and
rs7336518) credibility judgments based on the 90% sets. One of
these has a discordant effect (rs7610856) while the others have a
concordant effect on SZ and EA.
Overall, our analyses suggest that some of the 21 SNPs that we
identiﬁed by using EA as a proxy-phenotype for SZ are likely to
have direct pleiotropic effects on both traits. Of the most likely
candidates for direct pleiotropic effects, three SNPs have
concordant signs (rs79210963, rs7336518 and rs320700) and
one has discordant signs (rs7610856).
Biological annotations. Biological annotation of the 132 SNPs
that are jointly associated with EA (PEA < 10−5) and SZ (PSZ <
0.05) using DEPICT (Supplementary Note 4 and Supplementary
Data 5–7) points to genes that are known to be involved in
neurogenesis and synapse formation (Supplementary Data 8).
Some of the indicated genes, including SEMA6D and CSPG5,
have been suggested to play a potential role in SZ31,32.
For the two novel candidate SNPs reported in this study
(rs7522116 and rs7336518), DEPICT points to the FOXO6
(Forkhead Box O6) and the SLITRK1 (SLIT and NTRK Like
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Family Member 1) genes, respectively. FOXO6 is predominantly
expressed in the hippocampus and has been suggested to be
involved in memory consolidation, emotion and synaptic
function33,34. Similarly, SLITRK1 is also highly expressed in the
brain35, is particularly localized to excitatory synapses and
promotes their development36, and it has previously been
suggested to be a candidate gene for neuropsychiatric disorders37.
LD-aware enrichment across different traits. The raw enrich-
ment P value reported in Fig. 2b could in principle be due to the
LD structure of the EA lead SNPs that we tested. Speciﬁcally, if
these EA lead SNPs have stronger LD with other SNPs in the
human genome than expected by chance, this could cause the
observed enrichment of this set of SNPs on SZ and other traits
because higher LD increases the chance these SNPs would ‘tag’
causal SNPs that they are correlated with38,39.
To assess the null hypothesis that the observed genetic
dependence between EA and SZ can be entirely explained by
LD patterns in the human genome, we developed an association
enrichment test that corrects for the LD score of each SNP. We
applied this test to the 132 SNPs that are jointly associated with
EA (PEA < 10−5) and SZ (PSZ < 0.05), i.e. the loci that were
identiﬁed by using EA as a proxy-phenotype for SZ. LD scores
were obtained from the HapMap 3 European reference panel40
(Supplementary Data 9). We found signiﬁcant joint LD-aware
enrichment for SZ (P= 9.57 × 10−66), demonstrating that the
genetic dependence between EA and SZ cannot be entirely
explained by LD.
Furthermore, we used this test to explore if these SNPs are
generally enriched for association with all (brain-related) pheno-
types, or whether they exhibit some degree of outcome speciﬁcity.
For this purpose, we extended the LD-aware enrichment test to
21 additional traits for which GWAS results were available in the
1) EA GWAS (Okbay et al. 2016)
N = 363,502 individuals
12,299,530 SNPs
2) SZ GWAS (Ripke et al. 2014)
(PGC - GRAS excluded)
N = 34,409 cases
N = 45,670 controls
17,221,718 SNPs
8,240,280 SNPs
Overlap
EA_all
EA_all
pEA < 10–5
506 SNPs
132 SNPs
21 SNPs
Bonferroni
pSZ = 0.05/506
2 SNPs
novel for SZ
SZ_all
EA_132 SZ_132
8,240,280 SNPs
3) Proxy-phenotype
4) Schizophrenia diagnosis prediction in the GRAS sample
N = 1054 cases/N = 1169 controls
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Fig. 1 Workﬂow of the proxy-phenotype analyses. Notes: Educational attainment (EA) and schizophrenia (SZ) GWAS results are based on the analyses
reported in refs.5, 8. All cohorts that were part of the SZ GWAS were excluded from the meta-analysis on EA. The GRAS data collection was not included in
either the SZ or the EA meta-analysis. Proxy-phenotype analyses were conducted using 8,240,280 autosomal SNPs that passed quality control. Genetic
outliers of non-European descent (N= 13 cases) were excluded from the analysis in the GRAS data collection
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public domain (Supplementary Fig. 5 and Supplementary
Data 10). Some of the traits were chosen because they are
phenotypically related to SZ (e.g. neuroticism, depressive
symptoms, major depressive disorder, autism and childhood
IQ), while others were less obviously related to SZ (e.g. age at
menarche, intracranial volume and cigarettes per day) or served
as negative controls (height, birth weight, birth length and fasting
(pro)insulin). The power of the LD-aware enrichment test
primarily depends on the GWAS sample size of the target trait
and results of our test would be expected to change as GWAS
sample sizes keep growing. We found LD-aware enrichment of
these SNPs for BIP, neuroticism, childhood IQ and age at
menarche. However, we found no LD-aware enrichment for other
brain-traits that are phenotypically related to SZ, such as
depressive symptoms, subjective well-being, autism and attention
deﬁcit hyperactivity disorder. We also did not ﬁnd LD-aware
enrichment for most traits that are less obviously related to the
brain and our negative controls. Furthermore, one of the novel
SNPs we isolated shows signiﬁcant LD-aware enrichment both
for SZ and for BIP (rs7522116). The results suggest that the loci
identiﬁed by the PPM are not simply related to all (brain) traits.
Instead, they show some degree of phenotype speciﬁcity.
Replication in the GRAS sample. Following our preregistered
analysis plan (https://osf.io/dnhfk/), we replicated the PPM ana-
lysis results in the GRAS sample (Supplementary Note 5 and
Supplementary Data 11) using polygenic prediction (Supple-
mentary Note 6, Supplementary Data 12 and Supplementary
Fig. 6). The PGS (SZ_132) that is based on the 132 independent
EA lead SNPs that are also nominally associated with SZ (PEA <
10−5 and PSZ < 0.05) adds ΔR2= 7.54− 7.01%= 0.53%
predictive accuracy for SZ case–control status to a PGS (SZ_all)
derived from the GWAS on SZ alone (P= 1.7 × 10−4, Supple-
mentary Data 13, Model 3).
Prediction of SZ measures among patients. To explore the
genetic architecture of speciﬁc SZ measures, we again used our
replication sample (GRAS), which contains exceptionally detailed
measures of SZ symptoms, severity and disease history4,7,27. We
focused on years of education, age at prodrome, age at disease
onset, premorbid IQ (approximated by a multiple-choice voca-
bulary test), global assessment of functioning (GAF), the clinical
global impression of severity (CGI-S) as well as positive and
negative symptoms (PANSS positive and negative, respectively)
among SZ patients (N ranges from 903 to 1039, see Supple-
mentary Note 5). Consistent with the idea that EA is a predictor
of SZ measures, our phenotypic correlations show that higher
education is associated with later age at prodrome, later onset of
disease and less severe disease symptoms among SZ patients
(Supplementary Note 7, Supplementary Data 15 and Supple-
mentary Fig. 7).
Our most direct test for genetic heterogeneity of SZ is based on
PGS analyses that we performed using the detailed SZ measures
among GRAS patients. If SZ is genetically heterogeneous, there is
potentially relevant information in the sign concordance of
individual SNPs with EA traits that may improve the prediction
of symptoms (Supplementary Note 1). We use a simple method
to do this here: ﬁrst, we construct a PGS for SZ that contains one
SNP per LD-block that is most strongly associated with SZ.
Overall, this score (SZ_all) contains 349,357 approximately LD-
independent SNPs. Next, we split SZ_all into two scores, based on
sign-concordance of the SNPs with SZ and EA. More speciﬁcally,
Table 1 SNPs signiﬁcantly associated with schizophrenia after Bonferroni correction
SNP-ID EA beta Signs
concordant
SZ adj. R2
(%)
SZ OR
(Adj.)
EAF Power α=
0.05/506 (%)
Chance of direct
pleiotropic effect
on EA and SZ
Posterior probability of true
association with SZ prior
belief (π) (%)
90%
sets
50%
sets
0.1% 1.0% 5.0% 10.0%
rs79210963 −0.016 Yes 0.021 0.931 0.89 22.9 H M 75.0 96.8 99.3 99.7
rs7610856 0.013 No 0.022 0.955 0.41 22.8 M M 74.9 96.8 99.3 99.7
rs10896636 0.012 No 0.020 0.956 0.67 17.8 H L 68.7 95.6 99.1 99.5
rs756912 −0.015 Yes 0.022 0.956 0.51 22.7 L L 74.8 96.7 99.3 99.7
rs6449503 0.018 No 0.020 0.961 0.51 12.9 L L 60.0 93.7 98.7 99.3
rs7336518 −0.016 Yes 0.014 0.964 0.13 1.5 M M 13.4 60.6 88.5 93.9
rs143283559 0.014 No 0.017 0.965 0.72 4.6 M L 32.8 83.0 96.1 98.0
rs11210935 0.015 No 0.014 0.973 0.77 1.2 L L 10.9 55.1 86.0 92.5
rs77000541 −0.014 Yes 0.018 0.974 0.33 1.6 L L 14.1 62.2 89.2 94.3
rs2819344 0.014 No 0.017 0.983 0.62 0.3 H L 3.0 23.3 60.4 75.3
rs4500960 −0.013 No 0.017 1.017 0.47 0.3 L L 3.0 23.3 60.4 75.3
rs28360516 −0.012 No 0.013 1.027 0.70 1.4 M L 12.6 59.0 87.8 93.5
rs7522116 0.011 Yes 0.015 1.029 0.56 3.0 M L 23.8 75.8 94.0 96.9
rs7593947 0.014 Yes 0.018 1.040 0.51 12.5 M L 59.1 93.5 98.6 99.3
rs11694989 0.011 Yes 0.021 1.044 0.43 17.9 L L 68.8 95.7 99.1 99.5
rs320700 0.013 Yes 0.024 1.054 0.65 36.4 H M 85.3 98.3 99.7 99.8
rs3957165 0.015 Yes 0.020 1.056 0.83 14.7 L L 63.6 94.6 98.9 99.4
rs10791106 0.011 Yes 0.026 1.056 0.54 46.9 L L 89.9 98.9 99.8 99.9
rs2992632 0.016 Yes 0.025 1.060 0.74 36.8 M L 85.5 98.3 99.7 99.8
rs10773002 0.022 Yes 0.043 1.087 0.28 91.0 L L 99.0 99.9 100.0 100.0
rs4378243 0.019 Yes 0.044 1.112 0.85 91.5 L L 99.1 99.9 100.0 100.0
Notes: The SNPs in the table are ordered by their odds ratio (OR) on schizophrenia (SZ). Effect sizes for SZ (in R2 and OR) are downward adjusted for the winner’s curse25. EA (beta) is the standardized
beta of a SNP for educational attainment (EA) GWAS. R2 was approximated from the winner’s curse adjusted OR ratios, using the formulas described in Methods section. The winner’s curse adjustment
took into account that only SNPs with P= 0.05/506 were selected. SNPs with concordant effects on both SZ and EA are marked as ‘yes’ in the sign concordance column. EAF is the effect allele frequency
in the SZ GWAS data. Power calculations assumed that the available GWAS sample size for SZ for each SNP consisted of 34,409 cases and 45,670 controls. The chance that a SNP has direct pleiotropic
effects on EA and SZ has been evaluated with PAINTOR using sets of SNPs that have a cumulative probability of 90% or 50% to include the causal variant (see Methods and Supplementary Note 3). The
posterior probability that these SNPs are truly associated with SZ was calculated using the Bayesian procedure developed by Rietveld et al.25. SNPs highlighted in bold are associations for SZ that have
not been emphasized in the previous literature. H high, M medium, L low.
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one score contains all estimated SZ effects of SNPs that have
concordant signs for both traits (174,734 SNPs with ++ or −−
on both traits, Concordant) while the other contains the estimated
SZ effects of the remaining SNPs with discordant effects (174,623
SNPs with +− or −+, Discordant). Note that splitting the SZ_all
score this way is not expected to improve the prediction of
symptoms if they share the same genetic architecture (i.e. if SZ
was a genetically homogenous trait). We test this null hypothesis
with an F test that compares the predictive performance of
models that include (i) the SZ_all and the EA score (EA_all) and
(ii) the Concordant, Discordant, and EA_all scores (Supplemen-
tary Note 1). We also compare the performance of both of these
models to a baseline that only includes the SZ_all score as a
relevant predictor.
We found that the EA_all PGS is associated with years of
education (P= 1.0 × 10−6) and premorbid IQ (P= 2.7 × 10−4)
among SZ patients (Table 2). Consistent with earlier results4, we
also found that none of the SZ measures can be predicted by the
PGS for SZ (SZ_all, Table 2). However, splitting the PGS for SZ
based on the sign-concordance of SNPs with EA (Concordant and
Discordant) increased predictive accuracy signiﬁcantly for
severity of disease (GAF (pF= 0.023)) and symptoms (PANSS
negative (pF= 0.007)) (Table 2). This increase in predictive
accuracy is evidence for genetic heterogeneity of SZ (Supplemen-
tary Note 1). Speciﬁcally, our results indicate that SZ patients with
a high genetic propensity for EA have better GAFs and less severe
negative symptoms (PANSS negative). However, if the high
genetic predisposition for EA is primarily due to loci that also
increase the risk for SZ (i.e. high values on the Concordant score),
this protective effect is attenuated. We repeated these analyses
excluding patients who were diagnosed with schizoaffective
disorder (SD, N= 198) and found similar results, implying that
our ﬁndings are not only due to the presence of patients with SD
(Supplementary Note 8, Supplementary Data 18).
We note that this implementation of our test for heterogeneity
of SZ (Supplementary Note 1) is based on a conservative pruning
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Fig. 2 Results of the proxy-phenotype analyses. Notes: a Manhattan plot for educational attainment (EA) associations (n= 363,502). The x axis is the
chromosomal position, and the y axis is the signiﬁcance on a −log10 scale (two-sided). The black dashed line shows the suggestive signiﬁcance level of
10−5 that we speciﬁed in our preregistered analysis plan. Black and magenta crosses identify EA-associated lead-SNPs that are also associated with SZ at
nominal or Bonferroni-adjusted signiﬁcance levels, respectively. b Q–Q plot of the 506 EA-associated SNPs for schizophrenia (SZ) (n= 34,409 cases and
n= 45,670 controls). SNPs with concordant effects on both phenotypes are pink, and SNPs with discordant effects are blue. SNPs outside the grey area (21
SNPs) pass the Bonferroni-corrected signiﬁcance threshold that corrects for the total number of SNPs we tested (P < 0.05/506= 9.88 × 10−5) and are
labelled with their rs numbers. Observed and expected P values are on a −log10 scale. For the sign concordance test: P= 0.40, two-sided
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05510-z
6 NATURE COMMUNICATIONS |  (2018) 9:3078 | DOI: 10.1038/s41467-018-05510-z | www.nature.com/naturecommunications
algorithm that controls for LD both within and across the
Concordant and Discordant scores. This limits the number of
genetic markers in both of these scores, their expected predictive
accuracy and the power of the test. As an alternative, we also used
a less conservative approach that only prunes for LD within
scores, yielding 260,441 concordant and 261,062 discordant
SNPs. Split scores based on this extended set of SNPs have higher
predictive accuracy for all the SZ measures that we analysed
(Supplementary Data 22), reaching ΔR2= 1.12% (pF= 0.0004)
for PANSS negative.
Finally, we show that randomly splitting the SZ_all score does
not yield any gains in predictive accuracy (Supplementary
Data 19).
Genetic differences between SZ and bipolar. The ongoing
debate about what constitutes the difference between SZ and
BIP10–14 suggests an additional possibility to test for genetic
heterogeneity among SZ cases. While SZ and BIP share psycho-
tic symptoms such as hallucinations and delusions, scholars have
argued that SZ should be perceived as a neurodevelopmental
disorder in which cognitive deﬁcits precede the development of
psychotic symptoms, while this is not the case for BIP10–14.
However, cognitive deﬁcits during adolescence are currently not a
diagnostic criterion that formally differentiates SZ from BIP. As a
result, many patients who are formally diagnosed with SZ did not
suffer from cognitive impairments in their adolescent years, but
their disease aetiology may be different from those who do. These
differences in disease aetiology may be visible in how the non-
shared part of the genetic architecture of SZ and BIP is related to
measures of cognition, such as EA and childhood IQ.
We tested this by using genome-wide inferred statistics
(GWIS)41 to obtain GWAS regression coefﬁcients and standard
errors for SZ that are ‘purged’ of their genetic correlation with
BIP and vice versa (yielding ‘unique’ SZ(min BIP) and ‘unique’
BIP(min SZ) results, respectively). We repeated the look-up of the
EA-associated lead SNPs in those summary statistics and ﬁnd that
the enrichment is weaker than in the SZ GWAS results that did
not control for genetic overlap between SZ and BP (Supplemen-
tary Note 9).
We then computed genetic correlations of these GWIS results
with EA, childhood IQ and (as a non-cognitive control trait)
neuroticism using bivariate LD score regression42, and compared
the results to those obtained using ordinary SZ and BIP GWAS
results (Supplementary Note 10).
In line with earlier ﬁndings8,42, we see a positive genetic
correlation of ordinary SZ and BIP with EA. However, the genetic
correlations between ‘unique’ SZ(min BIP) with EA and childhood
IQ are negative and signiﬁcant (rg=−0.16, P= 3.88 × 10−4 and
rg=−0.31, P= 6.00 × 10−3, respectively), while the genetic
correlations of ‘unique’ BIP(min SZ) with EA and IQ remain
positive (rg ≈ 0.3) (Fig. 3, Supplementary Data 24). Thus, the
slightly positive genetic correlation between SZ and EA8,42 can be
entirely attributed to the genetic overlap between SZ and BIP41, a
result recently replicated using genomic structural equation
modelling43. Overall, these results add to the impression that
current clinical diagnoses of SZ aggregate over various non-
identical disease aetiologies.
Simulating assortative mating. Finally, simulations show that
assortative mating is unlikely to be a major cause of the observed
level of genetic dependence between EA and SZ (Supplementary
Note 11, Supplementary Fig. 9).
Discussion
We explored the genetic relationship between EA and SZ using
large, non-overlapping GWAS samples. Our results show that
EA-associated SNPs are much more likely to be associated with
SZ than expected by chance, i.e. both traits are genetically
dependent. Overall, we isolated 21 genetic loci that are credibly
associated with SZ by using EA as a proxy-phenotype, including
two novel candidate genes, FOXO6 and SLITRK1. Furthermore,
we showed that EA GWAS results help to predict future GWAS
ﬁndings for SZ in even larger samples.
Table 2 Polygenic prediction of schizophrenia measures in the GRAS patient sample
Years of
educationa
Age at
prodrome
Age at
disease onset
Premorbid
IQa
GAFb CGI-Sb PANSS
positiveb
PANSS
negativeb
Baseline model
SZ_all Stand.
beta
0.001 −0.041 −0.056 −0.063 −0.024 0.041 0.033 0.043
P value 0.976 0.297 0.129 0.090 0.510 0.249 0.364 0.253
EA_all Stand.
beta
0.182** 0.005 −0.002 0.149** 0.068* −0.057 0.001 −0.051
P value 4.4 × 10−09 0.884 0.961 7.2 × 10−6 0.029 0.065 0.981 0.107
Adj. R² 0.0612 0.0023 0.0047 0.0417 0.0655 0.0816 0.0711 0.0243
ΔAdj. R²c 0.0312 −0.0010 −0.0009 0.0209 0.0035 0.0023 −0.0010 0.0015
Split model
Concordant Stand.
beta
−0.013 −0.019 −0.031 −0.043 −0.096* 0.050 0.079 0.125**
P value 0.751 0.665 0.456 0.326 0.022 0.232 0.059 0.0036
Discordant Stand.
beta
0.014 −0.030 −0.035 −0.034 0.066 <0.001 −0.039 −0.072
P value 0.730 0.515 0.409 0.437 0.112 0.996 0.351 0.090
EA_all Stand.
beta
0.191** 0.002 −0.002 0.153** 0.122** −0.074 −0.039 −0.118**
P value 1.0 × 10−06 0.965 0.953 2.7×10−4 0.002 0.058 0.319 0.003
Adj. R² 0.0604 0.0012 0.0037 0.0406 0.0694 0.0811 0.0728 0.0306
ΔAdj. R²c 0.0304 −0.0021 −0.0019 0.0198 0.0074 0.0018 0.0007 0.0078
n 1039 915 1043 903 1010 1014 1009 1002
ΔR² (Split−baseline
model)
−0.0008 −0.0011 −0.0010 −0.0011 0.0039 −0.0005 0.0017 0.0063
P value from F testd 0.698 0.907 0.968 0.891 0.023* 0.479 0.098 0.007**
Notes: Linear regression using the ﬁrst ten genetic principal components as control variables aAge of onset was included as covariate bMedication was included as covariate cChange in Adj. R2 of the
models compared to a model that only contains the SZ_all score and the control variables dP value from F test refers to improvement in split model compared to baseline model *Signiﬁcance at P o 0.05
**Signiﬁcance at P o 0.01 Stand standardized.
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Biological annotation of a broader set of SNPs that are jointly
associated with EA (PEA < 10−5) and SZ (PSZ < 0.05) points to
neurogenesis and synapse formation as potentially important
pathways that may inﬂuence both traits.
However, the genetic loci that are associated with both traits do
not follow a systematic sign pattern that would correspond to a
strong positive or negative genetic correlation. Our follow-up
analyses demonstrated that this pattern of strong genetic
dependence but weak genetic correlation between EA and SZ
cannot be fully explained by LD or assortative mating.
Instead, our results are most consistent with the idea that EA
and SZ are both genetically heterogeneous traits that aggregate
over various subphenotypes or symptoms with non-identical
genetic architectures. Speciﬁcally, our results suggest that current
SZ diagnoses aggregate over at least two disease subtypes: one
part resembles BIP and high IQ (possibly associated with Con-
cordant SNPs), where better cognition may also be genetically
linked to other BIP features such as higher energy and drive,
while the other part is a cognitive disorder that is independent of
BIP (possibly inﬂuenced by Discordant SNPs). This latter subtype
bears similarity with Kraepelin’s description of dementia prae-
cox11. Overall, our pattern of results resonates with the idea that
cognitive deﬁcits in early life may be an important differentiating
factor between patients with BIP versus SZ psychosis.
Moreover, splitting the PGS for SZ into two scores based on the
sign concordance of SNPs with EA enables the prediction of
disease symptoms and severity from genetic data for the ﬁrst time
to some extent. We showed that this result is not driven by
patients with SD and it cannot be repeated by randomly splitting
the SZ score. Obviously, further replication of our results in other
samples with high-quality SZ measures would be highly desirable.
The many sign-concordant loci that increase the risk for SZ but
also improve the chance for higher education point to possible
side-effects of pharmacological interventions that may aim to
target biological pathways that are implicated by pleiotropic loci.
Indeed, exploring pleiotropic patterns of disease-associated genes
across a broad range of phenotypes (including social-scientiﬁc
ones such as EA or subjective well-being26) may be a viable
strategy to identify possible side-effects of new pharmacological
products at early stages of drug development in the future.
Although the complexity of SZ remains astonishing, our study
contributes to unravelling this complexity by starting at a genetic
level of analysis using well-powered GWAS results. Our results
provide some hope that a psychiatric nosology that is based on
biological causes rather than pure phenotypical classiﬁcations
may be feasible in the future. Studies that combine well-powered
GWASs of several diseases and from phenotypes that represent
variation in the normal range such as EA are likely to play an
important part in this development. However, deep phenotyping
of large patient samples will be necessary to link GWAS results
from complex outcomes such as EA and SZ to speciﬁc biological
disease subgroups.
Methods
GWAS. The principal investigators of all cohorts obtained informed consent from
all study participants and approval from Institutional Review Boards (IRB) at their
respective institution. We obtained GWAS summary statistics on EA from the
SSGAC. The results are based on Okbay et al.8, including the UK Biobank. The
PGC shared GWAS summary statistics on SZ with us that were reported in Ripke
et al.5, but excluded data from our replication sample (GRAS), yielding a total
sample size of n= 34,409 cases and n= 45,670 controls.
All cohorts that were part of both studies5,8 were excluded from the meta-
analysis on EA, yielding non-overlapping GWAS samples and nEA= 363,502. The
original EA results ﬁle contained 12,299,530 genetic markers, compared to
17,221,718 in the SZ results ﬁle.
We applied the following additional quality control steps:
1. To maximize statistical power, we excluded SNPs that were missing in large
parts of the two samples. Speciﬁcally, we continued with SNPs that were
available in at least 19 out of 50 cohorts in the SZ results5 (the actual N per
SNP was not provided in the SZ GWAS summary statistics) and in N >
200,000 in the EA meta-analysis8. This step excluded 3,778,914 and 6,369,138
genetic markers for EA and SZ, respectively.
2. We dropped SNPs that were not available in both GWAS results ﬁles. This
step restricted our analyses to the set of available genetic markers that passed
the quality-control ﬁlters in both the EA and the SZ GWAS results, leaving us
with 8,403,560 autosomal SNPs.
3. We dropped six SNPs with non-standard alleles (i.e. not A, C, T or G) and
two SNPs with mismatched effective alleles. Furthermore, we dropped 163,272
SNPs in the ﬁrst and the 99th percentile of the distribution of differences in
MAF in the two results ﬁles. This ﬁnal step eliminated SNPs that were likely to
be affected by coding errors, strand ﬂips or substantial differences in MAF in
the EA and SZ samples.
The remaining 8,240,280 autosomal SNPs were used in the proxy-phenotype
and prediction analyses.
Proxy-phenotype method. Look-up: We conducted our proxy-phenotype analyses
following a pre-registered analysis plan (https://osf.io/dnhfk/), using the 8,240,280
autosomal SNPs that passed quality control. We selected 10−5 as the default P
value threshold to identify EA-associated SNPs prior to carrying out the proxy-
phenotype analyses (Supplementary Note 2).
To select approximately independent SNPs from the EA GWAS results, we
applied the clumping procedure in PLINK version 1.944,45 using r2 > 0.1 and
1,000,000 kb as the clumping parameters and the 1000 Genomes phase 1 version 3
European reference panel46 to estimate LD among SNPs. This algorithm assigns
the SNP with the smallest P value as the lead SNP in its ‘clump’. All SNPs in the
vicinity of 1,000,000 kb around the lead SNP that are correlated with it at r2 > 0.1
are assigned to this clump. The next clump is formed around the SNP with the next
smallest P value, consisting of SNPs that have not been already assigned to the ﬁrst
clump. This process is iterated until no SNPs remain with P < 10−5, leading to 506
approximately independent EA-associated lead SNPs. 108 of the 506 EA-associated
lead SNPs are genome-wide signiﬁcant (P < 5 × 10−8).
We looked up the SZ GWAS results for these 506 EA-associated lead SNPs.
Results for all 506 SNPs are reported in Supplementary Data 2 and Fig. 2.
In order to investigate the novelty of the ﬁndings, we extracted all the SNPs in
LD with these 21 SNPs at r2 ≥ 0.1 with a maximum distance of 1000 kb using the
1000 Genomes phase 1 European reference panel.
Bayesian credibility of results: We probed the credibility of our proxy-
phenotype association results using a heuristic Bayesian calculation following
Rietveld et al. (Supplementary Information pp. 13–15)25. We focus on the 21 EA-
associated lead SNPs that are also associated with SZ after Bonferroni correction.
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Bayes’ rule implies that the probability that an association is true given that we
observe signiﬁcance is given by
P H1jt>tα=2
 
¼ P t>tα=2 jH1ð ÞP H1ð Þ
P t>tα=2 jH1ð ÞP H1ð ÞþP t>tα=2 jH0ð ÞP H0ð Þ
¼ ðpowerÞðπÞpowerð Þ πð ÞþðαÞð1πÞ
‘Power’, as well as the signiﬁcance test, are two-sided, π is the prior belief that
the SNP is truly associated and α is the signiﬁcance threshold used for testing (in
our case, α= 0:05506 = 9.88 × 10
−5).
To calculate power for each SNP, we computed the winner’s curse corrected OR
using the procedure described in Rietveld et al. (Supplementary Information pp. 7–
13)47 for the α threshold of 9.88 × 10−5. Because the actual sample size per SNP is
not reported in the SZ GWAS summary statistics, we furthermore assumed that
each SNP was available in the entire sample of 34,409 cases and 45,670 controls (i.e.
the PGC results from Ripke et al.5 excluding the GRAS data collection).
An important question is which prior beliefs are reasonable starting points for
these Bayesian calculations. For an arbitrarily chosen SNP, the most conservative
reasonable prior would assume that each truly associated SNP has the same effect
size as the strongest effect size that was actually observed in the data. If one divides
the SNP-based heritability of the trait by that effect size in R2 units, one obtains a
lower bound for the number of SNPs that can be assumed to be truly associated. To
aid this line of thinking, we converted the winner’s curse corrected OR of our 21
SNPs into R2 using
R2 ¼ dﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d2 þ ap
 2
where d is Cohen’s d, which is calculated as
d ¼ lnðOddsÞ
ﬃﬃ
3
p
π
and a is a correction factor that adjusts for the MAF of the SNP. This correction
factor is calculated as
a ¼ n1 þ n2ð Þ
2
n1n2
where n1=N ×MAF and n2=N × (1−MAF)48.
The largest effect size in R2 that we observe in our results is rs4378243 with
0.044%. The SNP-based heritability of SZ is ≈21%49. Thus, if all causal SZ SNPs
would have an effect of R2= 0.044%, we would expect that ≈500 truly causal loci
exist. The chance of ﬁnding any one of them by chance from a set of ≈500,000
independent loci in the human genome is ≈0.1%. (Our pruning algorithm of SNPs
that passed QC leads to only 223,065 independent loci. Thus, assuming 500,000
independent loci in these calculations is conservative.) However, in reality most
truly associated loci for SZ will surely have smaller effects than that. Thus, a prior
belief of ≈0.1% is certainly too conservative.
Furthermore, the SNPs we investigate are not arbitrary but selected based on
their association with another, genetically related cognitive trait (EA) in a very
large, independent sample. Thus, a prior belief of 1 or 5% that these SNPs are also
associated with SZ is probably more reasonable. As an upper bound, we assume
that 10% of all loci are causal. Thus, the chance to pick any one of them by chance
would be 10%.
Table 1 displays the winner’s curse corrected effect size of the 21 EA-associated
lead SNPs that are also associated with SZ after Bonferroni correction. It also shows
the posterior probability that these SNPs are truly associated with SZ given our
results for prior beliefs ranging from 0.1, 1, 5 to 10%. Thirteen of these SNPs have
posterior probabilities of being true positives of >50% for even the most
conservative prior. For a more realistic prior belief of 5%, all 21 SNPs are likely or
almost certain to be true positives.
Sign concordance: We compared the signs of the beta coefﬁcients of the 506 EA
lead SNPs (PEA < 10−5) with the beta coefﬁcients for SZ. If the signs were aligned,
we assigned a ‘1’ to the SNP and ‘0’ otherwise. By chance, sign concordance is
expected to be 50%. We tested if the observed sign concordance is different from
50% using the binomial probability test50. 263 of the 506 SNPs have the same sign
(52%, P= 0.40, two-sided).
Sign concordance is 58% (P= 0.10, two-sided) in the set of 132 EA lead SNPs
that are also nominally signiﬁcant for SZ (PEA < 1 × 10−5 and PSZ < 0.05).
Finally, for the 21 SNPs that passed Bonferroni correction for SZ (PEA < 1 ×
10−5 and PSZ < 9.88 × 10−5), sign concordance is 62% (P= 0.38, twosided).
Raw enrichment factor (not corrected for LD score of SNPs): Because EA and
SZ are highly polygenic, we tested for enrichment by taking the actual distribution
of P values in the GWAS result ﬁles into account.
Due to the polygenic architecture of both traits, it is expected to ﬁnd some EA-
associated SNPs that are also associated with SZ just by chance even if both traits
are genetically independent. Under this null hypothesis, the expected number of
EA-associated lead SNPs that are also signiﬁcantly associated with SZ is
EH0 NS;EA!SZ
h i
¼ NT;EA ´ τPEA ´ τPSZ
where NT,EA is the total number of independent lead SNPs in the EA GWAS
results, and τPEA and τPSZ are the shares of SNPs in NT,EA that have P values for EA
and SZ below a certain threshold, respectively.
We deﬁne the raw enrichment factor as
NS;EA!SZ=E NS;EA!SZ
h i
where NS,EA→SZ is the observed independent number of SNPs that pass both the P
value thresholds PEA and PSZ.
We obtained NT,EA by applying the clumping procedure described above (PPM)
without a P value threshold for EA, leading to 222,289 independent EA lead SNPs
in our merged GWAS results ﬁle. For PEA < 10−5, we found 506 SNP (τPEA =
506
222;289
= 0.2276%).
The Bonferroni threshold for testing 506 independent hypothesis is PSZ < 0:05506 =
9.88 × 10−5. There are 341 independent SNPs in the SZ results that pass this
threshold, thus τPSZ =
341
222;289= 0.1534%. Therefore, we expect [NS,EA→SZ]=
222,289 × 0.2276% × 0.1534%= 0.776 (i.e. less than one) SNP to be jointly
associated with both traits under the hull hypothesis of no genetic overlap. At these
P value thresholds, we actually observe NS,EA→SZ= 21 SNPs, implying a raw
enrichment factor of 210:776= 27.
For PSZ < 0.05, we found 17,935 SNP (τPSZ =
17;935
222;289= 8.068%). Thus, [NS,EA→SZ]
= 222,289 × 0.2276% × 8.068%= 41. At this more liberal P value threshold, we
actually observe NS,EA→SZ= 132 SNPs, implying a raw enrichment factor of 13241 =
3.23.
Raw enrichment P value (not corrected for LD score of SNPs): Following Okbay
et al.26, we performed a non-parametric test of joint enrichment that probes
whether the EA lead SNPs are more strongly associated with SZ than randomly
chosen sets of SNPs with MAF within one percentage point of the lead SNP. To
perform our test, we randomly drew ten matched SNPs for each of the 506 EA lead
SNPs with PEA < 10−5.
We then ranked the 506 × 10 randomly matched SNPs and the original 506 lead
EA SNPs by P value and conducted a Mann–Whitney test51 of the null hypothesis
that the P value distribution of the 506 EA lead SNPs are drawn from the same
distribution as the 506 × 10 randomly matched SNPs. We reject the null hypothesis
with P= 6.872 × 10−10 (Z= 6.169, two-sided). As a negative control test, we also
calculated the raw enrichment P value of the ﬁrst randomly drawn, MAF-matched
set of SNPs against the remaining nine sets, yielding P = 0.17.
Repeating this raw enrichment test for the subset of 21 EA-associated SNPs that
remained signiﬁcantly associated with SZ after Bonferroni correction (threshold
PSZ < 0:05506 = 9.88 × 10
−5) yields P= 5.44 × 10−14 (Z= 7.521, two-sided). The
negative control test based on the raw enrichment P value of the ﬁrst randomly
drawn, MAF-matched set of SNPs against the remaining nine sets yields P= 0.34.
GWAS catalogue look-up. In order to investigate the novelty of the 21 SNP
associations that were found signiﬁcant for SZ after Bonferroni correction, reported
in Table 1, we performed a look-up in the GWAS catalogue52 (revision 2016-08-25,
downloaded on 2016-08-29, https://www.ebi.ac.uk/gwas/api/search/downloads/
full) with the SNPs and all their ‘LD partners’ (i.e. all SNPs with an r2 > 0.5 within a
250 kb window). The LD partners were extracted with PLINK44 using a version of
the 1000G reference panel speciﬁcally harmonized to combine 1000G phase 1 and
phase 3 imputed data53, and the reference panel has been described previously26.
The result of the GWAS catalogue look-up is reported in Supplementary Data 3.
Prediction of future GWAS loci for SZ. To identify LD partners and to clump our
GWAS results, we used a threshold of r2 > 0.1 and a 1,000,000 kb window in the
1000 Genomes phase 1 version 3 European reference panel. Our SZ summary
statistics contained 51,721 approximately independent SNPs with PSZ < 0.05. We
identiﬁed 21,430 SNPs in LD with the 50 novel SNPs reported in ref.28 and 54,425
SNPs in LD with the 128 genome-wide signiﬁcant loci that were previously
reported5. We removed SNPs in LD with the previously GWAS hits from our
analyses because those SNPs could (by deﬁnition) not be identiﬁed as novel. The
remaining set of 51,528 approximately independent SNPs with PSZ < 0.05 in our SZ
GWAS results contained one proxy for each of the 50 novel SNPs in ref.28. After
removing SNPs in LD with previous GWAS hits, 110 SNPs with PSZ < 0.05 also
exhibited PEA < 10−5 in the independent EA GWAS sample. Of those 110 SNPs, six
were identiﬁed as novel SZ loci in the most recent GWAS dataset expansion28.
Using Fisher’s exact test, we rejected the null hypothesis that the proportion of
novel SNPs (6/110 vs 50/51528) is equal in the two sets (P= 2.4 × 10−9, two-sided).
Furthermore, as a robustness check, we performed the analysis again by excluding
the SNPs with MAF ≤ 0.1 and found similar results (P= 1.2 × 10−6). Thus, we
conclude that conditioning GWAS results on SZ with independent GWAS evidence
on EA signiﬁcantly outperforms pure chance in predicting GWAS results on SZ
from even larger samples.
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Pleiotropy between EA and SZ. To explore if the loci identiﬁed by our PPM may
have direct pleiotropic effects on EA and SZ, we applied genetic ﬁne mapping using
full GWAS results for both traits. Our procedure was as follows:
First, the SZ and EA GWAS results were merged into a single ﬁle and aligned
such that the reference allele is identical. Ambiguous SNPs or SNPs which may be
subject to strands ﬂips were removed. Second, all SNPs within 500 kb upstream and
downstream of the 21 signiﬁcant lead SNPs from the PPM analyses were extracted.
The pairwise LD between all SNPs in each window was computed. We then ran
PAINTOR 3.030 which estimates the posterior probability of any SNP within a
locus to be causal. We applied this procedure for EA and SZ. We then selected a
90% credibility set for EA and SZ, which reﬂects the broadest possible set of SNPs
whose posterior probability covers 90% of the total posterior probability at that
locus. We predetermined the maximum number of true causal loci to be 2. For the
EA 90% credibility set, we then determined the posterior probability that this set
contains the causal locus for SZ and vice versa. As the size of this set ﬂuctuates
between <1% of the locus size to ~30% of the total locus size (i.e. a more narrow set
can be identiﬁed for some loci compared to others), we also computed 80, 65 and
50% credibility sets for EA and SZ (Supplementary Note 3 and Supplementary
Data 4), which all have increasingly narrower sets of SNPs (the 50% credibility set
is the narrowest set we investigated). Finally, we compute the ratio of the cross trait
credibility for the 90% sets and the proportion of SNPs in the locus, which reﬂects
the enrichment of signal over the baseline where each SNP is equally credible. We
classify the probability of a locus being pleiotropic as low, medium, or high if the
posterior probability of both the EA set on SZ and the SZ set on EA are <15, 15–45
or >45% respectively.
Biological annotations. To gain insights into possible biological pathways that are
indicated by the PPM results, we applied DEPICT8,54 using a false discovery rate
threshold of ≤0.05. DEPICT is a data-driven integrative method that uses recon-
stituted gene sets based on massive numbers of experiments measuring gene
expression to (1) prioritize genes and gene sets and (2) identify tissues and cell
types wereprioritised genes are highly expressed. The input for our analyses
(DEPICT version 1 release 194) were the 132 EA lead SNPs that are also nominally
associated with SZ.
For these 132 EA lead SNPs, we also used DEPICT to determine the enrichment
of expression in particular tissues and cell types by testing whether the genes
overlapping the GWAS loci are highly expressed in any of 209 Medical Subject
Heading (MeSH) annotations.
To identify independent biological groupings, we computed the pairwise
Pearson correlations of all signiﬁcant gene sets using the ‘network_plot.py’ script
provided with DEPICT. Next, we used the Afﬁnity Propagation method on the
Pearson distance matrix for clustering55. The Afﬁnity Propagation method
automatically chooses an exemplar for each cluster.
Furthermore, we prioritize genes using DEPICT. Any particular locus centred
on a SNP may contain multiple genes. One straightforward approach is to
nominate a gene that is closest to the SNP. But this approach does not consider if
the expression of the gene is likely to be altered or regulated by the causal site in the
locus. Therefore, we used DEPICT to map genes to associated loci, which prioritize
important genes that share similar annotations in bioinformatic databases.
Signiﬁcant reconstituted gene sets, tissues, cell types and prioritized genes
identiﬁed by DEPICT are described in Supplementary Note 4.
LD-aware enrichment of PPM results across different traits. For SNP i in trait
j, the expected χ2 statistic can be calculated as
E Z2ij
h i
¼ Nj ´ h2j ´ LDscorei=M
 
þ ð1þ NaÞj
where N is the sample size of the target trait j, h2 is the heritability of trait j,
LDscorei=
PM
k¼1
r2ik for SNP i is calculated using HapMap3 SNPs from European-
ancestry,M is the number of SNPs included in the calculation of the LD score (n=
1,173,569 SNPs), r2jk is the squared correlation between SNPs j and k in the
HapMap3 reference panel and 1+Na is the LD score regression intercept for trait
j.
To determine whether a particular realization is signiﬁcantly larger than
expected (and thus the ratio χ2observed/χ2expected is signiﬁcantly greater than one), we
test each particular observed Z statistic (the square root of the χ2) for SNP j against
a normal distribution with variance: (Nj × h2j × LDscorei/M)+ (1+Na)j.
We used precomputed LD scores available from the LDSC software38. As
recommended by Bulik-Sullivan et al.38, we restricted our analysis to HapMap3
SNPs (using the merge-alleles ﬂag) because these seem to be well-imputed in most
studies. Out of 132 SNPs with PEA < 1 × 10−5and PSZ < 0.05, only 30 SNPs are
directly present in HapMap3 SNP list (Supplementary Data 9). Therefore, we
extracted proxy SNPs with r2 > 0.8 and a maximum distance of 500 kb to our
missing EA lead SNPs and chose the one with the highest r2 as a proxy. After this
step, we could include 105 (out of 132) SNPs in our analyses. For each of these 105
SNPs, we observed the Z-statistics in the publicly available GWAS results of the
traits. Z-statistics were converted into χ2 statistics by squaring them. The LD score
corrected enrichment per SNP for each trait is the ratio of the observed to the
expected χ2.
Furthermore, since the SNPs considered for enrichment are independent, we
can use Fisher’s method to combine the enrichment P values per SNP into a single
P value per trait. The latter P value reﬂects excess enrichment for the set of SNPs
beyond what is expected if these SNPs are part of the inﬁnitesimal genetic
contribution to the trait in question.
The results are shown in Supplementary Fig. 5 (and in Supplementary Data 10).
Our LD-aware enrichment test has two limitations. First, LD score regression
assumes that allele frequency (AF) does not correlate with effect size, an
assumption which has been empirically shown to be violated for low-frequency
alleles56. Second, our test assumes the absence of selection on the trait. Variation in
AF and the degree of negative selection could explain excess signal in low LD
SNPs57. However, our raw enrichment P value is robust to this because it takes the
AF of the candidate SNPs explicitly into account.
Replication of PPM results in the GRAS data collection. The GRAS data col-
lection complies with the Helsinki Declaration and were approved by the Ethics
Committees of the Universities of Göttingen and Greifswald, Germany or of col-
laborating centres. All subjects and/or their authorized legal representatives gave
written informed consent.
We showed in our pre-registered analysis plan that our replication sample
(GRAS) is not large enough to replicate individual SNPs (https://osf.io/dnhfk/).
Instead, we decided at the outset to attempt replication of the proxy-phenotype
analysis results using a PGS that consists of the >80 most strongly associated,
independent SNPs. The set that best meets this criterion are the 132 independent
EA lead SNPs that are also nominally associated with SZ (PSZ < 0.05). PGS for this
set of 132 candidate SNPs were constructed using either the β coefﬁcient estimates
of the EA or the SZ GWAS meta-analysis, resulting in two different scores (named
EA_132 and SZ_132).
In addition, we also constructed PGS for EA, SZ, BIP and neuroticism in the
GRAS data collection using all available SNPs as control variables for multivariate
prediction analyses (named EA_all, SZ_all, BIP_all and Neuro_all). Technical
details are described below.
Polygenic score calculations in the GRAS data collection. PGS were calculated
using PLINK version 1.944,45. We calculated eight different scores, which are
described below. Supplementary Fig. 6 shows the distribution of the MAFs of all
SNPs that were included in these PGS.
SZ scores: We received the GWAS summary statistics for SZ from the PGC
excluding the data from our replication sample (GRAS). We constructed a PGS
using the 132 EA lead SNPs (PEA < 10−5) that are also nominally associated with
SZ (PSZ < 0.05). This score (SZ_132) is used for replication of the proxy-phenotype
analyses.
Furthermore, we constructed a PGS using all 8,240,280 SNPs that survived
quality control (SZ_all). Next, we applied the clumping procedure using r² > 0.1
and 1000 kb as the clumping parameters and the 1000 Genomes phase 1 version 3
European reference panel to estimate LD among SNPs, eventually leaving a set of
349,357 SNPs ready for proﬁle scoring. The vast majority of the SNPs we included
in the SZ PGS (79%) have MAF > 1% and MAF < 99% (Supplementary Fig. 6).
For secondary analyses on the prediction of SZ symptoms, we constructed two
PGS using the 349,357 SNPs that have concordant (+ and +; or – and –) or
discordant signs (+ and –; or – and +) for EA and SZ, respectively. This resulted in
174,734 and 174,623 independent SNPs with concordant or discordant,
respectively. We used these approximately independent SNPs for proﬁle scoring
and call the resulting PGS Concordant and Discordant. We note that this approach
of constructing the Concordant and Discordant scores is based on a very
conservative LD-pruning algorithm because we ﬁrst LD-pruned all SNPs that
survived quality control for both phenotypes and then sort them based on sign
concordance. Thus, this approach prunes for LD both within and across the
Concordant and Discordant scores.
As an alternative, we also used a less conservative approach that only prunes for
LD within scores. Speciﬁcally, this alternative approach ﬁrst sorts all SNPs that pass
quality control for both phenotypes (8,240,280 SNPs) based on sign concordance
(4,147,926 SNPs with concordant and 4,092,354 SNPs with discordant signs) and
then LD-prunes the resulting set, yielding 260,441 and 261,062 independent SNPs
with concordant or discordant, respectively. We call the PGS resulting from this
approach Concordant_more_SNPs and Discordant_more_SNPs.
To enable tests for the sensitivity of our results to the MAF distribution of SNPs
included in our scores, we also constructed PGS using SNPs with MAF > 1% (i.e.
dropping SNPs with allele frequency ≤0.01 or ≥0.99) and with MAF > 10% (i.e.
dropping SNPs with allele frequency ≤0.10 or ≥0.90), respectively, from the
8,240,280 SNPs that survived quality control. Next, we used r2 > 0.1 and 1000 kb as
the clumping parameters and the 1000 Genomes phase 1 version 3 European
reference panel to estimate LD among SNPs, eventually leaving a set of 302,150
approximately independent lead-SNPs with MAF > 1% and 108,075 SNPs with
MAF > 10% ready for proﬁle scoring. The resulting scores are called SZ_all_1% and
SZ_all_10%, respectively. We also constructed PGS from this set of SNPs that took
the sign concordance between EA and SZ into account and call these PGS
Concordant_1% (151,265 SNPs), Discordant_1% (150,885 SNPs) and
Concordant_10% (54,287 SNPs), Discordant_10% (53,788 SNPs), respectively.
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All scores were calculated using the –score function in PLINK using the natural
log of the OR of the SNPs for SZ as effect sizes.
Educational attainment scores: Beta coefﬁcients for the EA GWAS were
approximated using bβj = zjﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃNj2MAFjð1MAFjÞp , see Rietveld et al.47 for the derivation.
Using these betas, we constructed a PGS using the 132 EA lead SNPs (PEA < 1 × 10
−5) that are also nominally associated with SZ (PSZ < 0.05). The resulting score is
called EA_132.
Furthermore, we constructed a PGS using all 8,240,280 SNPs that survived
quality control. Next, we applied the clumping procedure using r2 > 0.1 and 1000
kb as the clumping parameters and the 1000 Genomes phase 1 version 3 European
reference panel to estimate LD among SNPs, eventually leaving a set of 348,429
SNPs ready for proﬁle scoring (Supplementary Fig. 6). The resulting score is called
EA_all. Eighty percent of the SNPs we included in the EA PGS have MAF > 1% &
MAF < 99% (Supplementary Fig. 6).
We also constructed PGS using SNPs with MAF > 1% i.e. dropping SNPs with
allele frequency ≤0.01 or ≥0.99) and with MAF > 10% (i.e. dropping SNPs with
allele frequency ≤0.10 or ≥0.90), respectively, from the 8,240,280 SNPs that survived
quality control. Next, we used r2 > 0.1 and 1000 kb as the clumping parameters and
the 1000 Genomes phase 1 version 3 European reference panel to estimate LD
among SNPs, eventually leaving a set of 306,977 approximately independent lead-
SNPs with MAF > 1% and 106,607 SNPs with MAF > 10% ready for proﬁle scoring.
The resulting scores are called EA_all_1% and EA_all_10%, respectively.
BIP score: We obtained GWAS summary statistics on BIP from the PGC58. We
used the LD-pruned GWAS summary from PGC (‘pgc.bip.clump.2012–04.txt’)
with a set of 108,834 LD-pruned SNPs ready for proﬁle scoring. PGS for the GRAS
data collection were calculated by the application of the –score function in PLINK
using the natural log of the OR. The resulting score is called BIP_all.
Neuroticism score: We obtained GWAS summary statistics on Neuroticism
from the SSGAC. The results are based on the analyses reported in Okbay et al.26
containing 6,524,432 variants. We applied the clumping procedure using r2 > 0.1
and 1000 kb as the clumping parameters and the 1000 Genomes phase 1 version 3
European reference panel to estimate LD among SNPs, eventually leaving a set of
232,483 SNPs ready for proﬁle scoring (Supplementary Fig. 6). PGS for the GRAS
data collection were calculated by the application of –score function in PLINK using
the Neuroticism beta values. The resulting score is called Neuro_all.
Note that our replication sample (GRAS) was not included in the GWAS
summary statistics of any of these traits.
Polygenic score correlations: We calculated Pearson correlations between all
PGS that we constructed in the GRAS data collection (SZ_all, SZ_132, EA_all,
EA_132, Concordant, Discordant, BIP_all and Neuro_all). Results for SZ patients
and healthy controls together are reported in Supplementary Data 12a. We found
very similar results among the SZ cases (Supplementary Data 12b) and healthy
controls when we analysed them separately from each other (Supplementary
Data 12c). These results were used to inform the correct multiple regression model
speciﬁcation for the polygenic prediction analyses (Supplementary Note 6 and 8).
GWIS. A GWIS infers genome-wide summary statistics for a (non-linear) function
of phenotypes for which GWAS summary statistics are available41. Here, in par-
ticular, we wish to infer for each SNP the effect on SZ, conditioned upon its effect
on BIP. One possible approximation involves a GWIS of the following linear
regression function:
SZ ¼ β  BIPþ e
where the parameter β is estimated from the genetic covariance between SZ and
BIP and the genetic variance in BIP as β=
covg SZ;BIPð Þ
varg ðBIPÞ . The residual (e) is actually
our trait of intrest, for which we use the term SZ(min BIP). Using GWIS we infer the
genome-wide summary statistics for SZ(min BIP) given the most recent PGC GWAS
results for SZ (omitting the GRAS data collection)5 and BIP59. The effect size with
respect to SZ(min BIP) for a single SNP is computed as:
eff sz  β  effBIP ¼ eff e
The standard error for each SNP effect is approximated using the delta method
and accounts for the possible effect of sample overlap between the SZ and BIP
GWAS.
As data input, we used the GWAS results on SZ (excluding the GRAS data
collection). GWAS results for BIP59 (6990 cases; 4820 controls) were obtained from
the website of the PGC (https://www.med.unc.edu/pgc/ﬁles/resultﬁles/pgc.cross.
bip.zip).
Using the same method and data, we also ‘purged’ the genetic association
results for BIP of their overlap with SZ, obtaining ‘unique’ BIP(min SZ) results.
Code availability. Source code for GWIS and LD-aware enrichment analyses are
available at https://github.com/MichelNivard/EA_SZ.
Data availability. The GWAS summary statistics that support the ﬁndings of this
study are available on the website of the SSGAC: http://www.thessgac.org/#!data/
kuzq8. The GRAS data collection is not publicly available due to data protection
laws in Germany that strictly safeguard the privacy ofstudy participants. To request
access, contact the study’s principal investigator Prof. Dr. Hannelore Ehrenreich
(ehrenreich@em.mpg.de)
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